FR2969610B1 - Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-indolinamide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) - Google Patents

Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-indolinamide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)

Info

Publication number
FR2969610B1
FR2969610B1 FR1061300A FR1061300A FR2969610B1 FR 2969610 B1 FR2969610 B1 FR 2969610B1 FR 1061300 A FR1061300 A FR 1061300A FR 1061300 A FR1061300 A FR 1061300A FR 2969610 B1 FR2969610 B1 FR 2969610B1
Authority
FR
France
Prior art keywords
indolinamide
pkb
pyrimidin
dihydro
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1061300A
Other languages
English (en)
Other versions
FR2969610A1 (fr
Inventor
Maurice Brollo
Jean-Christophe Carry
Victor Certal
Gilles Doerflinger
Ahmad Youssef El
Frank Halley
Karl Andreas Karlsson
Laurent Schio
Fabienne Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1061300A priority Critical patent/FR2969610B1/fr
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to PT118058494T priority patent/PT2658844T/pt
Priority to US13/977,396 priority patent/US9133168B2/en
Priority to SI201131075A priority patent/SI2658844T1/sl
Priority to EP11805849.4A priority patent/EP2658844B1/fr
Priority to LTEP11805849.4T priority patent/LT2658844T/lt
Priority to PCT/EP2011/073875 priority patent/WO2012089633A1/fr
Priority to PL11805849T priority patent/PL2658844T3/pl
Priority to DK11805849.4T priority patent/DK2658844T3/en
Priority to ES11805849.4T priority patent/ES2612492T3/es
Priority to HUE11805849A priority patent/HUE030393T2/en
Publication of FR2969610A1 publication Critical patent/FR2969610A1/fr
Application granted granted Critical
Publication of FR2969610B1 publication Critical patent/FR2969610B1/fr
Priority to HRP20170119TT priority patent/HRP20170119T1/hr
Priority to CY20171100117T priority patent/CY1118858T1/el
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR1061300A 2010-12-28 2010-12-28 Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-indolinamide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) Expired - Fee Related FR2969610B1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR1061300A FR2969610B1 (fr) 2010-12-28 2010-12-28 Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-indolinamide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
HUE11805849A HUE030393T2 (en) 2010-12-28 2011-12-22 New pyrimidine derivatives, a process for their preparation, and their pharmaceutical use as inhibitors of AKT (PKB) phosphorylation
SI201131075A SI2658844T1 (sl) 2010-12-28 2011-12-22 Novi derivati pirimidina, njihova priprava in njihova farmacevtska uporaba kot inhibitorje AKT(PKB) fosforilacije
EP11805849.4A EP2658844B1 (fr) 2010-12-28 2011-12-22 Nouveaux derives de pyrimidines, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
LTEP11805849.4T LT2658844T (lt) 2010-12-28 2011-12-22 Nauji pirimidino dariniai, jų gamyba ir jų farmacinis panaudojimas kaip akt (pkb) fosforilinimo slopiklių
PCT/EP2011/073875 WO2012089633A1 (fr) 2010-12-28 2011-12-22 Nouveaux derives de pyrimidines, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
PT118058494T PT2658844T (pt) 2010-12-28 2011-12-22 Novos derivados de pirimidinas, sua preparação e utilização farmacêutica como inibidores de fosforilação de akt (pkb)
DK11805849.4T DK2658844T3 (en) 2010-12-28 2011-12-22 HIS UNKNOWN PYRIMIDINE DERIVATIVES, PREPARING THEREOF AND PHARMACEUTICAL USE THEREOF AS ACTIVE (PKB) PHOSPHORATION INHIBITORS
ES11805849.4T ES2612492T3 (es) 2010-12-28 2011-12-22 Nuevos derivados de piridiminas, su preparación y su utilización farmacéutica como inhibidores de fosforilación de AKT (PKB)
US13/977,396 US9133168B2 (en) 2010-12-28 2011-12-22 Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
PL11805849T PL2658844T3 (pl) 2010-12-28 2011-12-22 Nowe pochodne pirymidyn, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT(pkb)
HRP20170119TT HRP20170119T1 (hr) 2010-12-28 2017-01-25 Novi derivati pirimidina, njihovo pripremanje, te njihova farmaceutska uporaba kao inhibitora akt (pkb) fosforilacije
CY20171100117T CY1118858T1 (el) 2010-12-28 2017-01-26 Νεα παραγωγα πυριμιδινης, παρασκευη αυτων και φαρμακευτικη χρηση αυτων ως αναστολεων φωσφορυλιωσης ακτ(ρκβ)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1061300A FR2969610B1 (fr) 2010-12-28 2010-12-28 Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-indolinamide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)

Publications (2)

Publication Number Publication Date
FR2969610A1 FR2969610A1 (fr) 2012-06-29
FR2969610B1 true FR2969610B1 (fr) 2013-04-05

Family

ID=44141019

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1061300A Expired - Fee Related FR2969610B1 (fr) 2010-12-28 2010-12-28 Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-indolinamide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)

Country Status (1)

Country Link
FR (1) FR2969610B1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008148074A2 (fr) * 2007-05-24 2008-12-04 Research Foundation Of State University Of New York Inhibiteurs de mtor et methodes de traitement mettant en œuvre ces inhibiteurs
SI2448927T1 (sl) * 2009-07-02 2014-06-30 Sanofi Novi (6-okso-1,6-dihidro-pirimidin-2-il)-amidni derivati, njihova priprava in njihova farmacevtska uporaba kot AKT fosforilacijski inhibitorji
AR077628A1 (es) * 2009-07-02 2011-09-14 Sanofi Aventis Derivados de 6-(morfolin-4-il)-pirimidin-4(3h)-ona, su preparacion y su utilizacion farmaceutica como inhibidores de la fosforilacion de akt(pkb)

Also Published As

Publication number Publication date
FR2969610A1 (fr) 2012-06-29

Similar Documents

Publication Publication Date Title
FR2954317B1 (fr) Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
WO2011153157A3 (fr) Inhibiteurs benzoquinolone de vmat2
FR2954315B1 (fr) Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
SI2658844T1 (sl) Novi derivati pirimidina, njihova priprava in njihova farmacevtska uporaba kot inhibitorje AKT(PKB) fosforilacije
WO2012082436A3 (fr) Modulateurs d'histone méthyltransférase et leurs procédés d'utilisation
ME01269B (me) Jedinjenja pirolo (2,3-d) pirimidina
WO2011153514A9 (fr) Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
EA201290147A1 (ru) Пирроло[2,3-d]пиримидиновые соединения
IL224288A (en) Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
WO2014011900A3 (fr) Inhibiteurs du récepteur du facteur de croissance de fibroblastes
MA34069B1 (fr) Dérivés de n-(imidazopyrimidin-7-yl)hétéroarylamide et leur utilisation comme inhibiteurs de pde10a)
MX2013004491A (es) Boronatos como inhibidores de arginasa.
WO2013078170A8 (fr) Purification d'anticorps anti-c-met
WO2011113060A3 (fr) Composés antiviraux et procédés d'utilisation de ceux-ci
WO2012021715A3 (fr) Formulations stables de linaclotide
MA28941B1 (fr) Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2010068292A8 (fr) Dérivés d'azaindole en tant qu'inhibiteurs de kinases
FR2896504B1 (fr) Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2011150201A3 (fr) Composés azolylamide et leurs procédés d'utilisation
ZA201200026B (en) Novel (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide derivatives,preparation thereof,and pharmaceutical use thereof as akt(pkb) phosphorylation inhibotors
WO2012016042A3 (fr) Marqueurs de masse moléculaire à base d'acétate de glatiramer
WO2011123524A3 (fr) Macrolides inhibiteurs de mtor
BR112015005562A2 (pt) compostos de aminoisoquinolina, suas composições e uso dos novos compostos como inibidores da proteína quinase.
EP2551266A4 (fr) Composés non nucléosidiques de 2',2-dithiazole, leurs procédés de préparation, compositions pharmaceutiques et utilisations en tant qu'inhibiteurs de virus de l'hépatite
FR2941952B1 (fr) Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20160831